🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

RecruitingPhase 3Ages 18 Years - anyAllJonsson Comprehensive Cancer Center
NCT07461948 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI) are effective as non-invasive methods for assessing the cells and proteins that surround and interact with tumor cells (the tumor immune microenvironment) in patients with glioblastoma. Researchers understand that some types of brain tumors are harder to treat than others, but the reasons for this are not known in many cases. CEST MRI uses differences in the tissue microenvironment, like protein concentration or intracellular pH, to generate contrast differences. DR-CSI detects microstructural changes in tissue associated with immune cells infiltrating the tumor. Fe-MRI uses ferumoxytol as a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male or female ≥ 18 years of age * Documentation of a confirmed or suspected diagnosis of glioblastoma * The participant is scheduled to undergo standard of care surgical tumor resection and/or biopsy * The participant has a measurable contrast-enhancing lesion (\> 1ml) based on the most recent MRI prior to resection/biopsy Exclusion Criteria: * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data * Individuals who cannot tolerate MRI scan, or with contraindication to 3-Tesla (3T) MRI * Any abnormalities that would be a contraindication to iron-oxide nanoparticle-based contrast agent. Medical history will be gathered from the patient and clinical chart. The information will be reviewed with medical professionals (Doctor of Medicine \[MD\]) to determine the eligibility of the patient
💊

What it tests

  • Biospecimen Collection
  • Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
  • Diffusion-Relaxation Correlation Spectrum Imaging
  • Electronic Health Record Review
  • Ferumoxytol
📍

Where

1 site
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy